Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan.
In 2001, Japan launched a national influenza immunisation program for the elderly which provides a subsidy. In order to evaluate the efficiency of the strategy taken in this current program which provides 71% subsidy for all and explore alternative strategies, authors carried out a cost-effectiveness analysis. Authors compared strategies with different levels of subsidy and the use of risk-base targeting by constructing a decision tree model based on the literature. Incremental cost-effectiveness ratios of alternative strategies were estimated deterministically and probabilistically from societal perspective. Probabilistically estimated mean incremental cost-effectiveness ratio of current strategy is US$ 15,535 per YOLS, which can be concluded that current program is cost-effective. Authors also conclude that switching from current strategy to strategy which provides 100% subsidy for all, or strategy which provides 100% subsidy for high-risk elderlies only, can be cost-effective as well.
Hoshi
Shu-Ling
SL
University of Tsukuba, Graduate School of Comprehensive Human Sciences, Doctoral Program in Human-Care Sciences, Department of Health Care Policy and Management, Japan. s0335772@ipe.tsukuba.ac.jp
Kondo
Masahide
M
Honda
Yasushi
Y
Okubo
Ichiro
I
D000368:Aged / Q000706:statistics & numerical data*; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D003663:Decision Trees; D023381:Endpoint Determination; D006801:Humans; D007252:Influenza Vaccines / Q000191:economics*; D007251:Influenza, Human / Q000191:economics* / Q000276:immunology / Q000517:prevention & control*; D007564:Japan / Q000453:epidemiology; D008017:Life Expectancy; D032541:Mass Vaccination; D004366:Nonprescription Drugs / Q000191:economics; D018570:Risk Assessment
D007252:Influenza Vaccines; D004366:Nonprescription Drugs